Biocon Limited

WhiteOak Capital Mutual Fund bought 6,50,002 shares of Biocon Limited for ₹25.03 Cr at ₹385.00 apiece in a block deal.

A leading biotechnology company engaged in the manufacture of innovative pharmaceutical products and research services across multiple therapeutic areas. Biocon specializes in biologics, biosimilars, and small molecule drugs, serving patients in oncology, immunology, and diabetes therapeutics globally. The company operates integrated manufacturing facilities and maintains a strong commitment to developing affordable healthcare solutions for patients in emerging markets worldwide.

Founded by Prashant Khemka, former CIO of Goldman Sachs Asset Management India. Manages over Rs 20,000 crore with a concentrated bottom-up approach rooted in fundamental quality research. WhiteOak's edge is the proprietary SQGLP (Scalability, Quality, Growth, Longevity, Price) framework applied with global research standards to Indian equities.